{"analyses":[{"ciNumSides":"TWO_SIDED","ciPctValue":"95","groupDescription":"The event-free survival distributions of patients randomized to Regimen A - RA Only and randomized to Regimen B - RA + Immunotherapy were compared using the log-rank test.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.1016","paramType":"Log Rank Test Statistic","paramValue":"2.6803","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.4","upperLimit":"57.8","value":"48.1"},{"groupId":"OG001","lowerLimit":"54.0","upperLimit":"71.9","value":"62.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"description":"Comparison to determine if RA + Immunotherapy improves EFS as compared to RA Only","dispersionType":"95% Confidence Interval","groups":[{"description":"Randomized to Regimen A - RA Only","id":"OG000","title":"Regimen A"},{"description":"Randomized to Regimen B - RA + Immunotherapy","id":"OG001","title":"Regimen B"}],"paramType":"NUMBER","populationDescription":"Eligible, randomized patients.","reportingStatus":"POSTED","timeFrame":"Three years","title":"Event-Free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}